Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FRA: 496) announced on Friday it filed the required Business Acquisition Reports (BAR) in relation to the company’s previously announced acquisitions of Artisan Growers, Novo Formulations and Tassili Life Sciences.
The filings are part of Champignon’s commitment to work with the British Columbia Securities Commission (BCSC) to complete its previously announced disclosure review in a timely fashion. The review relates to the company’s disclosure obligations since it became a reporting issuer on February 6, 2020, and includes a review of the disclosure surrounding recent acquisitions completed by the company.
Champignon Brands also announced the appointment of company CEO, Dr. Roger McIntyre, to its Board of Directors. Dr. McIntyre will replace Pat McCutcheon as a director on the company’s board. Pat McCutcheon, CEO of MediPharm Labs (TSX: LABS) (OTCQX: MEDIF) (FRA: MLZ), will remain with the company in an advisory capacity, which will permit him increased mobility to assist Champignon with ongoing and planned capital markets initiatives.
Champignon Brands – Due Diligence – Research Links:
This U.S. Cannabis Stock Appears to Be Way Undervalued and May Actually Benefit From a Second Wave of the Pandemic
Champignon Brands is a paid client of The Cannabis Investor. The Cannabis Investor holds a position in Champignon Brands.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.